|Year : 2018 | Volume
| Issue : 1 | Page : 14-20
Autologous platelet-rich plasma for treatment of ischemic ulcers in buerger's disease: A pilot study with short-term results
Dhananjaya Sharma1, Pawan Agarwal1, Sharad Jain2, Reena Kothari1
1 Department of Surgery, Government Medical College and Allied Hospitals, Jabalpur, Madhya Pradesh, India
2 Department of Pathology, Government Medical College and Allied Hospitals, Jabalpur, Madhya Pradesh, India
|Date of Web Publication||31-Jan-2018|
Prof. Dhananjaya Sharma
Department of Surgery, Government Medical College and Allied Hospitals, Jabalpur, Madhya Pradesh
Source of Support: None, Conflict of Interest: None
Background: Many treatment modalities are available for the treatment of ischemic ulcers in Buerger's disease (thromboangiitis obliterans [TAO]). Objectives: The objective of the study was to evaluate the efficacy and clinical outcome of autologous platelet-rich plasma (PRP) for the treatment of ischemic ulcers in TAO patients. Methods: This prospective observational study was conducted on selected TAO patients who underwent autologous PRP treatment in surgery department of a teaching hospital in Central India. Diagnosis of TAO was made on clinical grounds and Color Doppler study. Autologous PRP was injected subcutaneously around the area of ulcer on day 0 and then on the 5th and 10th day. Results were noted on day 1, day 5, day 10, and on day 15. Outcome monitored was improvement in pain (using visual analog scale) and healing of ischemic ulcers. Results: All 14 patients were males, chronic smokers, and most of the patients were in the 4th decade of life. All had involvement of lower limbs; one had upper limb ischemia as well. All patients had ischemic ulcers. Pain relief, as measured with visual analog scale score, was good; most of the patients had 50% relief within 24 h of injecting PRP, which persisted/continued to improve on days 5, 10, and 15. Similarly, ulcer healing showed improvement on days 5, 10, and 15. Conclusions: PRP can provide efficient treatment for pain and healing of ischemic ulcers in TAO patients.
Keywords: Buerger's disease, healing, ischemic ulcer, platelet-rich plasma
|How to cite this article:|
Sharma D, Agarwal P, Jain S, Kothari R. Autologous platelet-rich plasma for treatment of ischemic ulcers in buerger's disease: A pilot study with short-term results. Indian J Vasc Endovasc Surg 2018;5:14-20
|How to cite this URL:|
Sharma D, Agarwal P, Jain S, Kothari R. Autologous platelet-rich plasma for treatment of ischemic ulcers in buerger's disease: A pilot study with short-term results. Indian J Vasc Endovasc Surg [serial online] 2018 [cited 2022 May 25];5:14-20. Available from: https://www.indjvascsurg.org/text.asp?2018/5/1/14/224446
| Introduction|| |
Buerger's disease aka thromboangiitis obliterans (TAO) is a nonatherosclerotic, segmental inflammatory disease that most commonly affects the small- and medium-sized arteries and veins in the lower extremities mainly affecting males smoking tobacco from the low socioeconomic strata. It is a common cause of peripheral vascular disease in India, Japan, Korea, and Bangladesh.,,
In the past decade, platelet-rich plasma (PRP) has become known as a reservoir of various growth factors which lead to neoangiogenesis and enhance wound healing.,,,,, Taking inspiration from these results, we studied the use of PRP in the treatment of ischemic ulcers in TAO patients.
| Methods|| |
This is a prospective observational study conducted on TAO patients in surgery department of a teaching hospital in Central India. It received due clearance from Institutional Ethics Committee.
Diagnosis of TAO was made on clinical grounds, supplemented with two-dimensional (2D) Color Doppler study as per Shionoya's criteria. Selected patients of TAO having ischemic ulcers (including those after excision of gangrenous patches and amputation of toes) were included in the present study. Patients were examined clinically, studied with 2D Color Doppler, and classified according to Rutherford and WIfI classifications [Table 1] and [Table 2].,, Symptom-free patients, those with deep ulcers and gangrene (Grade 6 of Rutherford classification and Grade 3 wound of WIfI classification, n = 20) and patients with diabetes (n = 1) and hypertension (n = 1) were excluded from the study. Selected patients were admitted in surgical ward. They were explained about their disease, benefit of complete abstinence from tobacco smoking/chewing was vigorously counseled, its compliance/noncompliance noted, and their informed consent was obtained in vernacular language.
Autologous PRP was freshly prepared, each time, by standard technique of differential centrifugation. A volume of 40 ml whole blood was obtained by venipuncture in acid citrate dextrose tubes. Blood was centrifuged using a “soft” spin at constant acceleration to separate red blood cells (RBCs) from the remaining blood volume. After the first spin step, the whole blood separates into three layers: an upper layer that contains mostly platelets and white blood cells (WBC), an intermediate thin layer that is known as the buffy coat and that is rich in WBCs, and a bottom layer that consists mostly of RBCs. The supernatant plasma containing platelets was then transferred into another sterile tube (without anticoagulant). This tube was then centrifuge tube at a higher speed, a “hard” spin, to obtain a platelet concentrate. The lower one-third is PRP and upper two-third is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed. Now, PPP was removed, and platelet pellets were homogenized in a minimum quantity of plasma (4 mL) by gently shaking the tube to create the PRP.
A volume of 4 ml PRP was injected subcutaneously around the area of ulcer with all due aseptic precautions on day 0 and then on the 5th and 10th day. Standard wound and foot care was given to all patients.
Pain relief was noted on day 1, day 5, day 10, and on day 15. Clinical improvement was noted in pain relief by visual analog scale (VAS) score of 0–10 (0 representing no pain and 10 maximum pain; pain score on day 0 was taken as 10). Ulcer healing results were noted on day 5, day 10, and on day 15. We constructed a simple grading system to denote the healing of ulcer. As shown in [Table 3], if healing was 0%–24%, it was graded as Grade 4, if healing was 25%–49%, it was graded as Grade 3, if healing was 50%–74%, it was graded as Grade 2, and if healing was 75%–100%, it was graded as Grade 1. Ulcer healing was noted by two observers (DS and PA). Kappa coefficient was used to check the degree of interobserver agreement.
Patients were asked to come for follow-up after 3 months, those who could not come were followed up by a telephone call.
Patients who could not complete the protocol of three injections were excluded from the final observations.
| Results|| |
Seventeen selected TAO patients with ischemic ulcers were given PRP treatment in surgery department of a teaching hospital in Central India from February 2017 to April 2017.
All patients were chronic bidi smokers, males; most of the patients were in the 4th decade (mean age 43.2 years, range 30–51 years) of life. Sixteen out of seventeen patients had unilateral involvement of lower limbs; one patient had upper limb involvement in addition to lower limb ischemia. Demographic data and results are shown in [Table 4].
Most of the patients were in Rutherford classification Grade 4 or 5 [Table 1]. All patients had ischemic ulcers (mean size 2.5 cm, range 2–5 cm), wound grade was I or II according to WIfI classification, ischemia grade was 3 (as per WIfI classification) in majority of the patients, while infection Grade varied from 0 to 2 [Table 2] and [Table 4].
Popliteal artery pulsations were present in all patients; however, ankle pressure index could not be measured in majority of the patients as their dorsalis pedis and posterior tibial arteries were not palpable [Table 4].
The actual process of injecting PRP subcutaneously around the ulcers was painful for patients. However, pain relief, as measured with VAS score, was good; most of the patients had 50% relief within 24 h of injecting PRP (mean VAS score 4.35), which persisted/continued to improve on days 5 (mean VAS score 4.35), 10 (mean VAS score 3.71), and 15 (mean VAS score 2.78) [Table 4]. Similarly, ulcer healing showed improvement on days 5, 10, and 15 [Table 3], [Table 4] and [Figure 1], [Figure 2], [Figure 3]. There was good interobserver agreement as kappa coefficient was 1.00.
|Figure 1: Clinical photograph of foot, Case no. 5 on (a) day 0 (b) day 15|
Click here to view
|Figure 2: Clinical photograph of foot, Case no. 10 on (a) day 0 (b) day 15|
Click here to view
|Figure 3: Clinical photograph of foot, Case no. 13 on (a) day 0 (b) day 15|
Click here to view
Three out of seventeen patients left before completing protocol; one of them could not give up tobacco and dropped out of protocol. These patients were excluded from the study, and outcome was observed in 14 patients.
Three out of fourteen patients came back after 3 months for follow-up and had good healing and pain relief. Seven out of fourteen patients reported, through telephone, good healing and pain relief. Three out of fourteen patients admitted, throughtelephone, to restarting tobacco smoking resulting in recurrence of disease; two had progression to gangrene of foot and had to undergo below-knee amputation at their respective district hospitals. One out of fourteen patients could not be contacted by telephone.
| Discussion|| |
PRP is defined as a small volume of plasma with a 4–7-fold increase in the concentration of platelets (at least 1,000,000 platelets/μL) above peripheral blood concentration., The use of PRP has been around for more than 30 years since, in 1986, Knighton et al. published the first clinical demonstration that autologous platelet-derived wound healing factors can stimulate repair of chronic nonhealing human wounds. PRP, when exposed to endothelium within wounds or damaged tissues, essentially forms an in situ-generated fibrin matrix delivery system, releasing multiple growth factors, chemokines, and cytokines including platelet-derived growth factor, vascular endothelial growth factor (VEGF), connective tissue growth factor, fibroblast growth factor, epidermal growth factor, transforming growth factor-beta, and other bioactive molecules that play key roles in tissue regeneration by enhancing in vivo angiogenesis, improving reperfusion/microcirculation, tissue remodeling, and enhanced wound healing.,,,,
An additional advantage of PRP is that its preparation does not need an expansive commercial kit. Recent advent of hand-powered ultralow-cost hand-spun paper centrifuge can circumvent nonavailability of even a mechanical/electrical centrifuge.
A variety of medicines are tried for the treatment of TAO. Best known among them are prostaglandin analogs which facilitate relaxation of vascular smooth cells, inhibit platelet aggregation, and show promise in reducing peripheral vascular resistance with vasodilatative effect. However, this effect is not seen with oral prostaglandin analogs.,, Recent Cochrane reviews have concluded that moderate-quality evidence suggests that intravenous iloprost (prostacyclin analog) is more effective than aspirin for eradicating rest pain and healing ischemic ulcers in Buerger's disease (even this benefit is transient), but oral iloprost is not more effective than placebo. Very low and low-quality evidence suggests that there is no difference between prostacyclin (iloprost and clinprost) and the prostaglandin analog alprostadil for healing ulcers and relieving pain, respectively, in severe Buerger's disease. However, no Randomized control trial (RCTs) have assessed other pharmacological agents such as cilostazol, clopidogrel, and pentoxifylline, and their usefulness remains unproven.,
Publication of groundbreaking paper by Asahara et al. in 1997 showed that endothelial progenitor cells were capable of being isolated from human peripheral blood and that they also retain the capacity to differentiate into mature and functional endothelial cells. Before the discovery of this cell type, new vessel formation was believed to occur “only” due to proliferation of existing endothelial cells. These findings have overturned the previous dogma that vasculogenesis can only occur during embryogenesis. This prompted a revolutionary change in thinking and application of therapeutic neoangiogenesis in the management of critical limb ischemia (CLI). This discovery led to the treatment of CLI, in both animal models and humans, by the use of peripheral blood/cord blood/adipose tissue/bone marrow mononuclear cells/stem cells.,,,,,,,,,,,,
Recent use of spinal cord stimulation has also led to a lot of interest among the research workers working in this field.,
Similarly, many surgical procedures are used for TAO. Popularity of sympathectomy stems from the fact that it reduces peripheral resistance by opening of arteriovenous anastomoses (both dependent on sympathetic vasoactivity), thereby increasing blood flow in skin. This effect, even though transient, allows ischemic ulcers to heal., Segmental nature of disease affecting small and medium-sized arteries limits endovascular/vascular reconstruction therapy to small number of patients in highly specialized centers. Once the feeding vessels have undergone thrombosis and obliteration – basic problem in TAO – only alternative left is to achieve neovascularization. Omentum is a source of angiogenic growth factors and stem cells which promote neovascularization. This property has been utilized by transposing the omentum in revascularization of the extremities.,,, Distraction osteogenesis, as shown by Ilizarov's landmark study, can stimulate and maintain regeneration, neoangiogenesis, and active growth of tissues not only in the bones but also in muscle, fascia, nerve, vessels, skin, and its appendages. This is called the “law of tension stress” and its beneficial effect has been seen in many studies in TAO.,, Even insertion of intramedullary K-wire has shown relief of pain and clinical improvement in TAO patients. Hypothetically, this may be due to the release of stem cells from bone marrow.
In our study, most of the patients had Grade 3 ischemia [as per WIfI classification, [Table 2] and [Table 4], and their dorsalis pedis and posterior tibial arteries were not clinically palpable and showed weak pulsations by Doppler, respectively, in five out of fourteen and eight out of fourteen patients. Platelets have a half-life of 4.6 days; hence, we injected PRP after 5-day interval. We obtained good pain relief and ulcer healing in 14 selected TAO patients with ischemic ulcers [Table 4]. Pain relief, as measured with VAS score, was quite dramatic as most of the patients had 50% relief within 24 h of injecting PRP, which persisted/continued to improve on days 5, 10, and 15 [Table 4]. Similarly, ulcer healing grades showed improvement on days 5, 10, and 15 [Table 3] and [Table 4]. We used kappa coefficient to demonstrate good interobserver agreement.
One patient with a history of bilateral sympathectomy [patient no. 10] and another patient with a history of bilateral sympathectomy and omental transposition [patient no: 10] had good ulcer healing and pain relief after PRP. This suggests that PRP is a good addition to the armamentarium of physicians treating ischemic ulcers in TAO patients when other avenues have been exhausted.
After PRP, it is possible to show improved perfusion, increased blood flow, and greater angiogenesis (greater presence of endothelial cells, collagen and VEGF, improved angiographic score, and increased capillary density)., However, in our study, these could not be shown more objectively as transcutaneous oxygen tension, toe brachial index, laser Doppler perfusion imaging, microangiography (showing improved angiographic score), and immune histology (showing increased capillary density) are not available in our setup.
The overall quality of evidence of autologous PRP for treating chronic wounds is low. There are many explanations for variability in the clinical benefit of PRP reported in the literature. the dose of platelets in PRP used may increase up to 25-fold increase depending on the amount injected, efficiency of preparation, activation of PRP, sustained release PRP, and leukocyte-rich PRP which releases more growth factors.,,
The fundamental principle of TAO management is “complete abstinence from tobacco.” We took pains to explain to the patients about etiology of TAO and vigorously counseled them about benefit of complete abstinence from tobacco. The management of TAO remains a multidisciplinary effort with emphasis on smoking cessation, pain control, and wound management, and moral support by family members is necessary. If patients start smoking again, the disease progression starts again, as seen in three out of fourteen of our patients. These patients confessed to a false sense of euphoria after their ulcers healed after PRP and mistakenly started smoking again.
Healing of ischemic ulcers in TAO needs total abstinence from tobacco, which is the cornerstone of preventing further progress of disease. Increased perfusion, even temporarily, can result in healing of these ulcers. All treatment modalities – prostaglandin analogs, stem cells, spinal cord stimulation, sympathectomy, omental transposition, and distraction osteogenesis led neoangiogenesis – aim at increasing perfusion. However, all these modalities have their inherent drawbacks; prostaglandin analogs are expansive, stem cells and spinal cord stimulation need upscale technology, and all surgical procedures are invasive and need indoor admission and anesthesia. In a global context, the Indian TAO patients are from the lowest socioeconomic strata which further limit their treatment options.
| Conclusions|| |
The use of autologous PRP fulfills the previously unmet need for treatment of TAO patients at grass-root level. It is very easy, reliable, and economical to prepare standard PRP and can be made available in the outpatient department of smallest of the hospitals. As the present observational study is based on a small number of patients, further validation in larger number of patients is desirable.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 2000;343:864-9.
Matsushita M, Nishikimi N, Sakurai T, Nimura Y. Decrease in prevalence of Buerger's disease in Japan. Surgery 1998;124:498-502.
Park UJ, Kim DI. Thromoboagiitis obliterans (TAO). Int J Stem Cells 2010;3:1-7.
Driver VR, Hanft J, Fylling CP, Beriou JM, Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 2006;52:68-70, 72, 74.
Frykberg RG, Driver VR, Carman D, Lucero B, Borris-Hale C, Fylling CP, et al.
Chronic wounds treated with a physiologically relevant concentration of platelet-rich plasma gel: A prospective case series. Ostomy Wound Manage 2010;56:36-44.
Sakata J, Sasaki S, Handa K, Uchino T, Sasaki T, Higashita R, et al.
retrospective, longitudinal study to evaluate healing lower extremity wounds in patients with diabetes mellitus and ischemia using standard protocols of care and platelet-rich plasma gel in a Japanese wound care program. Ostomy Wound Manage 2012;58:36-49.
Massara M, Barillà D, De Caridi G, Serra R, Volpe A, Surace R, et al.
Application of autologous platelet-rich plasma to enhance wound healing after lower limb revascularization: A case series and literature review. Semin Vasc Surg 2015;28:195-200.
Anitua E, Pelacho B, Prado R, Aguirre JJ, Sánchez M, Padilla S, et al.
Infiltration of plasma rich in growth factors enhances in vivo
angiogenesis and improves reperfusion and tissue remodeling after severe hind limb ischemia. J Control Release 2015;202:31-9.
Kontopodis N, Tavlas E, Papadopoulos G, Pantidis D, Kafetzakis A, Chalkiadakis G, et al.
Effectiveness of platelet-rich plasma to enhance healing of diabetic foot ulcers in patients with concomitant peripheral arterial disease and critical limb ischemia. Int J Low Extrem Wounds 2016;15:45-51.
Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol 1998;66 Suppl 1:S243-5.
Fontaine R, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders. Helv Chir Acta 1954;21:499-533.
Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al.
Recommended standards for reports dealing with lower extremity ischemia: Revised version. J Vasc Surg 1997;26:517-38.
Mills JL Sr, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, et al.
The society for vascular surgery lower extremity threatened limb classification system: Risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014;59:220-340.
Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: A Review and author's perspective. J Cutan Aesthet Surg 2014;7:189-97.
] [Full text]
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
Marx RE, Armentano L, Olavarria A, Samaniego J. RhBMP-2/ACS grafts versus autogenous cancellous marrow grafts in large vertical defects of the maxilla: An unsponsored randomized open-label clinical trial. Int J Oral Maxillofac Implants 2013;28:e243-51.
Pourmoussa A, Gardner DJ, Johnson MB, Wong AK. An update and review of cell-based wound dressings and their integration into clinical practice. Ann Transl Med 2016;4:457.
Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986;204:322-30.
Hargrave B, Li F. Nanosecond pulse electric field activated-platelet rich plasma enhances the return of blood flow to large and ischemic wounds in a rabbit model. Physiol Rep 2015;3. pii: E12461.
Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Król W, Wielkoszynski T, et al.
Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: An in vitro
study. J Bone Joint Surg Br 2007;89:417-20.
Chen L, Wang C, Liu H, Liu G, Ran X. Antibacterial effect of autologous platelet-rich gel derived from subjects with diabetic dermal ulcers in vitro
. J Diabetes Res 2013;2013:269527.
Fernandez-Moure JS, Van Eps JL, Cabrera FJ, Barbosa Z, Medrano Del Rosal G, Weiner BK, et al.
Platelet-rich plasma: A biomimetic approach to enhancement of surgical wound healing. J Surg Res 2017;207:33-44.
Kececi Y, Ozsu S, Bilgir O. A cost-effective method for obtaining standard platelet-rich plasma. Wounds 2014;26:232-8.
Bhamla MS, Benson B, Chai C, Katsikis G, Johri A, Prakash M. Hand-powered ultralow-cost paper centrifuge. Nature Biomed Eng 2017;1:9.
Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): A double-blind, randomised, placebo-controlled trial. The European TAO Study Group. Eur J Vasc Endovasc Surg 1998;15:300-7.
Chatziioannou A, Dalakidis A, Katsenis K, Koutoulidis V, Mourikis D. Intra-arterial prostaglandin e(1) infusion in patients with rest pain: Short-term results. ScientificWorldJournal 2012;2012:803678.
Bozkurt AK, Cengiz K, Arslan C, Mine DY, Oner S, Deniz DB, et al.
stable prostacyclin analogue (iloprost) in the treatment of Buerger's disease: A prospective analysis of 150 patients. Ann Thorac Cardiovasc Surg 2013;19:120-5.
Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2013;(4):CD000986.
Cacione DG, Macedo CR, Baptista-Silva JC. Pharmacological treatment for Buerger's disease. Cochrane Database Syst Rev 2016;3:CD011033.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al.
Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.
Ribatti D. The discovery of endothelial progenitor cells. An historical review. Leuk Res 2007;31:439-44.
Jadlowiec C, Brenes RA, Li X, Lv W, Protack CD, Collins MJ, et al.
Stem cell therapy for critical limb ischemia: What can we learn from cell therapy for chronic wounds? Vascular 2012;20:284-9.
Motukuru V, Suresh KR, Vivekanand V, Raj S, Girija KR. Therapeutic angiogenesis in buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J Vasc Surg 2008;48:53S-60S.
Matoba S, Tatsumi T, Murohara T, Imaizumi T, Katsuda Y, Ito M, et al.
Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic angiogenesis by cell transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008;156:1010-8.
Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010;209:10-7.
Kim AK, Kim MH, Kim S, Oh W, Hong HK, Kang KS, et al.
Stem-cell therapy for peripheral arterial occlusive disease. Eur J Vasc Endovasc Surg 2011;42:667-75.
Lee HC, An SG, Lee HW, Park JS, Cha KS, Hong TJ, et al.
Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: A pilot study. Circ J 2012;76:1750-60.
Brenes RA, Bear M, Jadlowiec C, Goodwin M, Hashim P, Protack CD, et al.
Cell-based interventions for therapeutic angiogenesis: Review of potential cell sources. Vascular 2012;20:360-8.
Yang SS, Kim NR, Park KB, Do YS, Roh K, Kang KS, et al.
phase I study of human cord blood-derived mesenchymal stem cell therapy in patients with peripheral arterial occlusive disease. Int J Stem Cells 2013;6:37-44.
Regulski MJ. Mesenchymal stem cells: “Guardians of inflammation”. Wounds 2017;29:20-7.
Sun L, Wu L, Qiao Z, Yu J, Li L, Li S, et al.
Analysis of possible factors relating to prognosis in autologous peripheral blood mononuclear cell transplantation for critical limb ischemia. Cytotherapy 2014;16:1110-6.
Yu JY, Li SZ, Wu LH, Li HM, Gao WH, Zheng YL, et al.
Preliminary clinical efficiency of autologous peripheral blood mononuclear cells for treating critical limb ischemia of thromboangiitis obliterans. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2016;24:892-6.
Wan J, Yang Y, Ma ZH, Sun Y, Liu YQ, Li GJ, et al.
Autologous peripheral blood stem cell transplantation to treat thromboangiitis obliterans: Preliminary results. Eur Rev Med Pharmacol Sci 2016;20:509-13.
Mohamed Omer S, Krishna SM, Li J, Moxon JV, Nsengiyumva V, Golledge J, et al.
The efficacy of extraembryonic stem cells in improving blood flow within animal models of lower limb ischaemia. Heart 2016;102:69-74.
Moazzami K, Moazzami B, Roohi A, Nedjat S, Dolmatova E. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev 2014;(12):CD008347.
Rivera-Chavarría IJ, Brenes-Gutiérrez JD. Thromboangiitis obliterans (Buerger's disease). Ann Med Surg (Lond) 2016;7:79-82.
Agarwal P, Sharma D. Spinal cord stimulation. In: Dieter RS, Dieter RA Jr., Dieter RA 3rd
, Nanjundappa A, editors. Critical Limb Ischemia: Acute and Chronic. Switzerland: Springer International Publishing; 2016. p. 465-8.
Agarwal P, Sharma D. Sympathectomy revisited: Current status in management of Critical limb Ischemia. In: Dieter RS, Dieter RA Jr., Dieter RA 3rd
, Nanjundappa A, editors. Critical Limb Ischemia: Acute and Chronic. Switzerland: Springer International Publishing; 2016. p. 459-64.
Kothari R, Maharaj A, Tomar TS, Agarwal P, Sharma D. Percutaneous chemical lumbar sympathectomy for Buerger's disease: Results in 147 patients. Indian J Vasc Endovasc Surg. In Press.
Casten DF, Alday ES. Omental transfer for revascularization of the extremities. Surg Gynecol Obstet 1971;132:301-4.
Nishimura A, Sano F, Nakanishi Y, Koshino I, Kasai Y. Omental transplantation for relief of limb ischemia. Surg Forum 1977;28:213-5.
Hoshino S, Nakayama K, Igari T, Honda K. Long-term results of omental transplantation for chronic occlusive arterial diseases. Int Surg 1983;68:47-50.
Agarwal VK. Long-term results of omental transplantation in chronic occlusive arterial disease (Buerger's disease) and retinal avascular diseases (retinitis pigmentosa). Int Surg 2007;92:174-83.
Ilizarov GA. The tension-stress effect on the genesis and growth of tissues: Part II. The influence of the rate and frequency of distraction. Clin Orthop Relat Res 1989;(239):263-85.
Shevtsov VI, Shurova EN, Shurov VA. Functional outcomes of legs obliterative endarteritis treatment by Ilizarov's method. Khirurgiia (Mosk) 1997;(6):47-50.
Patwa JJ, Krishnan A. Buerger's disease (Thromboangiitis obliterans)- management by ilizarov's technique of horizontal distraction. A Retrospective study of 60 cases. Indian J Surg 2011;73:40-7.
Kulkarni S, Kulkarni G, Shyam AK, Kulkarni M, Kulkarni R, Kulkarni V, et al.
Management of thromboangiitis obliterans using distraction osteogenesis: A retrospective study. Indian J Orthop 2011;45:459-64.
] [Full text]
Inan M, Alat I, Kutlu R, Harma A, Germen B. Successful treatment of Buerger's disease with intramedullary K-wire: The results of the first 11 extremities. Eur J Vasc Endovasc Surg 2005;29:277-80.
Cesar JM, Vecino AM. Survival and function of transfused platelets. Studies in two patients with congenital deficiencies of platelet membrane glycoproteins. Platelets 2009;20:158-62.
Kurita J, Miyamoto M, Ishii Y, Aoyama J, Takagi G, Naito Z, et al.
Enhanced vascularization by controlled release of platelet-rich plasma impregnated in biodegradable gelatin hydrogel. Ann Thorac Surg 2011;92:837-44.
Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Expósito JA, Bolíbar I, Rodríguez L, et al.
Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev 2016;(5):CD006899.
Bir SC, Esaki J, Marui A, Yamahara K, Tsubota H, Ikeda T, et al.
Angiogenic properties of sustained release platelet-rich plasma: Characterization in-vitro
and in the ischemic hind limb of the mouse. J Vasc Surg 2009;50:870-900.
Magalon J, Chateau AL, Bertrand B, Louis ML, Silvestre A, Giraudo L, et al.
DEPA classification: A proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc Med 2016;2:e000060.
Parrish WR, Roides B, Hwang J, Mafilios M, Story B, Bhattacharyya S, et al.
Normal platelet function in platelet concentrates requires non-platelet cells: A comparative in vitro
evaluation of leucocyte-rich (type 1a) and leucocyte-poor (type 3b) platelet concentrates. BMJ Open Sport Exerc Med 2016;2:e000071.
Klein-Weigel P, Volz TS, Zange L, Richter J. Buerger's disease: Providing integrated care. J Multidiscip Healthc 2016;9:511-8.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2], [Table 3], [Table 4]